Florida Cancer Specialists Advances GI Cancer Research with Multiple Clinical Trial Presentations
Event summary
- Florida Cancer Specialists & Research Institute (FCS) presented research at the ASCO Gastrointestinal Cancers Symposium in January 2026.
- Dr. Ivor Percent presented results from a Phase 2 study (1801 Part 3B) evaluating elraglusib plus gemcitabine/nab-paclitaxel (GnP) in pancreatic ductal adenocarcinoma.
- FCS physicians co-authored three additional studies focusing on novel treatments for colorectal and pancreatic cancers, including tovecimig (CTX-009) and ASP3082.
- ASP3082 is a first-in-class selective protein degrader being evaluated for KRAS G12D-mutant pancreatic ductal adenocarcinoma.
The big picture
FCS’s continued emphasis on clinical research and early-phase trials underscores a strategy to remain at the forefront of cancer treatment innovation. This approach allows them to offer patients access to cutting-edge therapies before they are widely available, potentially attracting patients and referrals. The focus on gastrointestinal cancers, a significant area of unmet need, highlights a targeted approach to research and development within the broader oncology market.
What we're watching
- Clinical Efficacy
- The results of the elraglusib study will be scrutinized to determine if the combination therapy demonstrates a statistically significant improvement in patient outcomes for mPDAC, potentially impacting treatment protocols.
- Pipeline Progress
- The advancement of ASP3082, a novel protein degrader, will be closely monitored as it moves through clinical trials, given the high unmet need for therapies targeting KRAS mutations.
- Competitive Landscape
- How FCS’s early access to and participation in clinical trials for novel therapies positions them relative to other oncology practices and influences patient recruitment and referral patterns remains to be seen.
Related topics